PIM1 is a Poor Prognostic Factor for and Potential Therapeutic Target in Serous Carcinoma of the Endometrium-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

PIM1 is a Poor Prognostic Factor for and Potential Therapeutic Target in Serous Carcinoma of the Endometrium

Published:2022-04-12 Issue:3 Volume:42 Page:282-292
ISSN:0277-1691
Container-title:International Journal of Gynecological Pathology
language:en
Short-container-title:

Author:

Takeuchi Hodaka,Miyamoto Tsutomu,Fuseya Chiho,Asaka Ryoichi,Ida Koichi,Ono Motoki,Tanaka Yasuhiro,Shinagawa Manaka,Ando Hirofumi,Asaka Shiho,Shiozawa Tanri

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Obstetrics and Gynecology,Pathology and Forensic Medicine

Reference35 articles.

1. Tumor estrogen content and clinico-morphological and endocrine features of endometrial cancer;Berstein;J Cancer Res Clin Oncol,2003

2. Uterine serous carcinoma: key advances and novel treatment approaches;Ferriss;Int J Gynecol Cancer,2021

3. Randomized phase II trial of carboplatin–paclitaxel compared with carboplatin–paclitaxel–trastuzumab in advanced (stage III–IV) or recurrent uterine serous carcinomas that overexpress Her2/Neu (NCT01367002): updated overall survival analysis;Fader;Clin Cancer Res,2020

4. A phase II trial of paclitaxel, carboplatin, and bevacizumab in advanced and recurrent endometrial carcinoma (EMCA);Simpkins;Gynecol Oncol,2015

5. Phase II study of the WEE1 inhibitor adavosertib in recurrent uterine serous carcinoma;Liu;J Clin Oncol,2021

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Enhanced MCM5 Level Predicts Bad Prognosis in Acute Myeloid Leukemia;Molecular Biotechnology;2022-12-07

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP